Robert Gross, MD
Neurology · Aurora, CONPI 1225358054
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $697 of the $1,060 with a category attached, or 65.8%. 7 manufacturers reported payments, led by Abbott at 34.2% of the total. Reporting peaked in 2024 at $670 and has fallen 56.6% since, to $291 in 2025. That places this record below the midpoint for neurology clinicians in CO, where the typical reported total is $699.
Across 22 payments — averaging $48.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$363
- Novartis$303
- Bristol Myers Squibb$134
- Medtronic$109
- EMD Serono, Inc.$94
- ANI Pharmaceuticals, Inc.$32
- plus $27 from 1 others
What the payments were for
- Travel & lodging$36334%
- Food & beverage$69766%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 2 | $363 |
| Novartis | 9 | $303 |
| Bristol Myers Squibb | 7 | $134 |
| Medtronic | 1 | $109 |
| EMD Serono, Inc. | 1 | $94 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Biogen | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,060 in reported general payments places this provider in the 50th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dalfampridine ErDalfampridine | 70 | $47,979 |
| Modafinil | 16 | $3,882 |
| Baclofen | 87 | $2,830 |
| Gabapentin | 100 | $2,632 |
| Duloxetine Hcl | 30 | $882 |
| AmantadineAmantadine Hcl | 16 | $775 |
| Pregabalin | 12 | $615 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $329 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $231 |
| Zolpidem Tartrate | 16 | $162 |
| Tizanidine Hcl | 11 | $132 |
| Diazepam | 15 | $51 |
| Tramadol Hcl | 12 | $18 |
Paid to pharmacies, not to this prescriber.
Other neurology in Aurora
- Jeffrey BennettAurora$605K
- Enrique AlvarezAurora$407K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Thomas RagoleAurora$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.